{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:38:51Z","timestamp":1787002731816,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16H05380"],"award-info":[{"award-number":["16H05380"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17H05930"],"award-info":[{"award-number":["17H05930"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H04887"],"award-info":[{"award-number":["19H04887"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["S2603"],"award-info":[{"award-number":["S2603"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["S2603"],"award-info":[{"award-number":["S2603"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K06977"],"award-info":[{"award-number":["18K06977"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["S2603"],"award-info":[{"award-number":["S2603"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["S2603"],"award-info":[{"award-number":["S2603"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008880","name":"Kanae Foundation for the Promotion of Medical Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20dm0107088"],"award-info":[{"award-number":["JP20dm0107088"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We have reported that a subpopulation of patients with schizophrenia have lower levels of vitamin B\n                    <jats:sub>6<\/jats:sub>\n                    (VB6) in peripheral blood than do healthy controls. In a previous study, we found that VB6 level was inversely proportional to the patient\u2019s positive and negative symptom scale (PANSS) score for measuring symptom severity, suggesting that the loss of VB6 might contribute to the development of schizophrenia symptoms. In the present study, to clarify the relationship between VB6 deficiency and schizophrenia, we generated VB6-deficient (VB6(\u2212)) mice through feeding with a VB6-lacking diet as a mouse model for the subpopulation of schizophrenia patients with VB6 deficiency. After feeding for 4 weeks, plasma VB6 level in VB6(\u2212) mice decreased to 3% of that in control mice. The VB6(\u2212) mice showed social deficits and cognitive impairment. Furthermore, the VB6(\u2212) mice showed a marked increase in 3-methoxy-4-hydroxyphenylglycol (MHPG) in the brain, suggesting enhanced noradrenaline (NA) metabolism in VB6(\u2212) mice. We confirmed the increased NA release in the prefrontal cortex (PFC) and the striatum (STR) of VB6(\u2212) mice through in vivo microdialysis. Moreover, inhibiting the excessive NA release by treatment with VB6 supplementation into the brain and \u03b12A adrenoreceptor agonist guanfacine (GFC) suppressed the increased NA metabolism and ameliorated the behavioral deficits. These findings suggest that the behavioral deficits shown in VB6(\u2212) mice are caused by enhancement of the noradrenergic (NAergic) system.\n                  <\/jats:p>","DOI":"10.1038\/s41398-021-01381-z","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T10:48:30Z","timestamp":1620038910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Vitamin B6 deficiency hyperactivates the noradrenergic system, leading to social deficits and cognitive impairment"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8593-3269","authenticated-orcid":false,"given":"Kazuya","family":"Toriumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7798-1834","authenticated-orcid":false,"given":"Mitsuhiro","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0038-4329","authenticated-orcid":false,"given":"Kazuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Yasumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0597-2514","authenticated-orcid":false,"given":"Yasue","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akane","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8079-8013","authenticated-orcid":false,"given":"Noriyoshi","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanari","family":"Itokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3400-9815","authenticated-orcid":false,"given":"Makoto","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"1381_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-10-273","volume":"10","author":"R Percudani","year":"2009","unstructured":"Percudani, R. & Peracchi, A. The B6 database: a tool for the description and classification of vitamin B6-dependent enzymatic activities and of the corresponding protein families. BMC Bioinforma. 10, 273 (2009).","journal-title":"BMC Bioinforma."},{"key":"1381_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10545-005-0243-2","volume":"29","author":"PT Clayton","year":"2006","unstructured":"Clayton, P. T. B6-responsive disorders: a model of vitamin dependency. J. Inherit. Metab. Dis. 29, 317\u2013326 (2006).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1381_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/pcn.12216","volume":"68","author":"M Arai","year":"2014","unstructured":"Arai, M. et al. Carbonyl stress and schizophrenia. Psychiatry Clin. Neurosci. 68, 655\u2013665 (2014).","journal-title":"Psychiatry Clin. Neurosci."},{"key":"1381_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archgenpsychiatry.2010.62","volume":"67","author":"M Arai","year":"2010","unstructured":"Arai, M. et al. Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch. Gen. Psychiatry 67, 589\u2013597 (2010).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1381_CR5","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1093\/schbul\/sbt129","volume":"40","author":"M Miyashita","year":"2014","unstructured":"Miyashita, M. et al. Clinical features of schizophrenia with enhanced carbonyl stress. Schizophr. Bull. 40, 1040\u20131046 (2014).","journal-title":"Schizophr. Bull."},{"key":"1381_CR6","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1093\/schbul\/sbt234","volume":"40","author":"N Katsuta","year":"2014","unstructured":"Katsuta, N. et al. Significance of measurements of peripheral carbonyl stress markers in a cross-sectional and longitudinal study in patients with acute-stage schizophrenia. Schizophr. Bull. 40, 1366\u20131373 (2014).","journal-title":"Schizophr. Bull."},{"key":"1381_CR7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1503\/jpn.170053","volume":"43","author":"Y Tomioka","year":"2018","unstructured":"Tomioka, Y. et al. Decreased serum pyridoxal levels in schizophrenia: meta-analysis and Mendelian randomization analysis. J. Psychiatry Neurosci. 43, 194\u2013200 (2018).","journal-title":"J. Psychiatry Neurosci."},{"key":"1381_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/pcn.12613","volume":"72","author":"M Itokawa","year":"2018","unstructured":"Itokawa, M. et al. Pyridoxamine: a novel treatment for schizophrenia with enhanced carbonyl stress. Psychiatry Clin. Neurosci. 72, 35\u201344 (2018).","journal-title":"Psychiatry Clin. Neurosci."},{"key":"1381_CR9","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1523\/JNEUROSCI.22-06-02335.2002","volume":"22","author":"Y Miyamoto","year":"2002","unstructured":"Miyamoto, Y. et al. Lower sensitivity to stress and altered monoaminergic neuronal function in mice lacking the NMDA receptor epsilon 4 subunit. J. Neurosci. 22, 2335\u20132342 (2002).","journal-title":"J. Neurosci."},{"key":"1381_CR10","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.euroneuro.2015.08.003","volume":"25","author":"K Toriumi","year":"2015","unstructured":"Toriumi, K. et al. Deletion of SHATI\/NAT8L decreases the N-acetylaspartate content in the brain and induces behavioral deficits, which can be ameliorated by administering N-acetylaspartate. Eur. Neuropsychopharmacol. 25, 2108\u20132117 (2015).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"1381_CR11","unstructured":"Franklin, K. & Paxinos, G. The Mouse Brain in Stereotaxic Coordinates (Academic Press, 2008)."},{"key":"1381_CR12","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/npp.2011.324","volume":"37","author":"K Toriumi","year":"2012","unstructured":"Toriumi, K. et al. Prenatal NMDA receptor antagonism impaired proliferation of neuronal progenitor, leading to fewer glutamatergic neurons in the prefrontal cortex. Neuropsychopharmacol. 37, 1387\u20131396 (2012).","journal-title":"Neuropsychopharmacol."},{"key":"1381_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.abb.2015.11.031","volume":"592","author":"JW Whittaker","year":"2016","unstructured":"Whittaker, J. W. Intracellular trafficking of the pyridoxal cofactor. Implications for health and metabolic disease. Arch. Biochem. Biophys. 592, 20\u201326 (2016).","journal-title":"Arch. Biochem. Biophys."},{"key":"1381_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.mam.2016.08.001","volume":"53","author":"PM Ueland","year":"2017","unstructured":"Ueland, P. M., McCann, A., Midttun, O. & Ulvik, A. Inflammation, vitamin B6 and related pathways. Mol. Asp. Med. 53, 10\u201327 (2017).","journal-title":"Mol. Asp. Med."},{"key":"1381_CR15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.pnpbp.2004.05.033","volume":"28","author":"K Yamamoto","year":"2004","unstructured":"Yamamoto, K. & Hornykiewicz, O. Proposal for a noradrenaline hypothesis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 28, 913\u2013922 (2004).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"1381_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/0361-9230(94)90167-8","volume":"35","author":"K Yamamoto","year":"1994","unstructured":"Yamamoto, K., Ozawa, N., Shinba, T., Hoshino, T. & Yoshii, M. Possible noradrenergic dysfunction in schizophrenia. Brain Res. Bull. 35, 529\u2013543 (1994).","journal-title":"Brain Res. Bull."},{"key":"1381_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.pnpbp.2005.04.003","volume":"29","author":"F Lechin","year":"2005","unstructured":"Lechin, F. & van der Dijs, B. Noradrenergic hypothesis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 777\u2013778 (2005).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"1381_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3177\/jnsv.44.37","volume":"44","author":"M Okada","year":"1998","unstructured":"Okada, M., Shibuya, M., Akazawa, T., Muya, H. & Murakami, Y. Dietary protein as a factor affecting vitamin B6 requirement. J. Nutr. Sci. Vitaminol. 44, 37\u201345 (1998).","journal-title":"J. Nutr. Sci. Vitaminol."},{"key":"1381_CR19","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1471-4159.1972.tb01374.x","volume":"19","author":"RA Bayoumi","year":"1972","unstructured":"Bayoumi, R. A., Kirwan, J. R. & Smith, W. R. Some effects of dietary vitamin B 6 deficiency and 4-deoxypyridoxine on -aminobutyric acid metabolism in rat brain. J. Neurochem. 19, 569\u2013576 (1972).","journal-title":"J. Neurochem"},{"key":"1381_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/ajcn\/48.2.291","volume":"48","author":"SP Coburn","year":"1988","unstructured":"Coburn, S. P. et al. Human vitamin B-6 pools estimated through muscle biopsies. Am. J. Clin. Nutr. 48, 291\u2013294 (1988).","journal-title":"Am. J. Clin. Nutr."},{"key":"1381_CR21","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1021\/bi00457a001","volume":"29","author":"D Palm","year":"1990","unstructured":"Palm, D., Klein, H. W., Schinzel, R., Buehner, M. & Helmreich, E. J. The role of pyridoxal 5'-phosphate in glycogen phosphorylase catalysis. Biochemistry 29, 1099\u20131107 (1990).","journal-title":"Biochemistry"},{"key":"1381_CR22","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1021\/bi00870a045","volume":"5","author":"JL Hedrick","year":"1966","unstructured":"Hedrick, J. L., Shaltliel, S. & Fischer, E. H. On the role of pyridoxal 5'-phosphate in phosphorylase. 3. Physicochemical properties and reconstitution of apophosphorylase b. Biochemistry 5, 2117\u20132125 (1966).","journal-title":"Biochemistry"},{"key":"1381_CR23","doi-asserted-by":"publisher","first-page":"6178","DOI":"10.1021\/jm049034y","volume":"48","author":"T Klabunde","year":"2005","unstructured":"Klabunde, T. et al. Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. J. Med. Chem. 48, 6178\u20136193 (2005).","journal-title":"J. Med. Chem."},{"key":"1381_CR24","first-page":"1377","volume":"19","author":"B Bondy","year":"1984","unstructured":"Bondy, B., Ackenheil, M., Birzle, W., Elbers, R. & Frohler, M. Catecholamines and their receptors in blood: evidence for alterations in schizophrenia. Biol. Psychiatry 19, 1377\u20131393 (1984).","journal-title":"Biol. Psychiatry"},{"key":"1381_CR25","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1001\/archpsyc.1988.01800330072009","volume":"45","author":"GN Ko","year":"1988","unstructured":"Ko, G. N., Jimerson, D. C., Wyatt, R. J. & Bigelow, L. B. Plasma 3-methoxy-4-hydroxyphenylglycol changes associated with clinical state and schizophrenic subtype. Arch. Gen. Psychiatry 45, 842\u2013846 (1988).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1381_CR26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000118821","volume":"25","author":"M Kaneko","year":"1992","unstructured":"Kaneko, M. et al. Plasma free 3-methoxy-4-hydroxyphenylglycol in acute schizophrenics before and after treatment. Neuropsychobiology 25, 126\u2013129 (1992).","journal-title":"Neuropsychobiology"},{"key":"1381_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1001\/archpsyc.1990.01810140061009","volume":"47","author":"DP van Kammen","year":"1990","unstructured":"van Kammen, D. P. et al. Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited. Arch. Gen. Psychiatry 47, 161\u2013168 (1990).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1381_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0165-1838(94)90127-9","volume":"50","author":"G Eisenhofer","year":"1994","unstructured":"Eisenhofer, G. et al. The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. J. Auton. Nerv. Syst. 50, 93\u2013107 (1994).","journal-title":"J. Auton. Nerv. Syst."},{"key":"1381_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0835-5","volume":"10","author":"AF Carvalho","year":"2020","unstructured":"Carvalho, A. F. et al. Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. Transl. Psychiatry 10, 152 (2020).","journal-title":"Transl. Psychiatry"},{"key":"1381_CR30","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.biopsych.2005.05.022","volume":"58","author":"BP Ramos","year":"2005","unstructured":"Ramos, B. P. et al. The beta-1 adrenergic antagonist, betaxolol, improves working memory performance in rats and monkeys. Biol. Psychiatry 58, 894\u2013900 (2005).","journal-title":"Biol. Psychiatry"},{"key":"1381_CR31","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S0006-3223(99)00138-9","volume":"46","author":"S Birnbaum","year":"1999","unstructured":"Birnbaum, S., Gobeske, K. T., Auerbach, J., Taylor, J. R. & Arnsten, A. F. A role for norepinephrine in stress-induced cognitive deficits: alpha-1-adrenoceptor mediation in the prefrontal cortex. Biol. Psychiatry 46, 1266\u20131274 (1999).","journal-title":"Biol. Psychiatry"},{"key":"1381_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40261-015-0336-0","volume":"36","author":"M Huss","year":"2016","unstructured":"Huss, M., Chen, W. & Ludolph, A. G. Guanfacine extended release: a new pharmacological treatment option in Europe. Clin. Drug Investig. 36, 1\u201325 (2016).","journal-title":"Clin. Drug Investig."},{"key":"1381_CR33","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1101\/lm.298006","volume":"13","author":"BP Ramos","year":"2006","unstructured":"Ramos, B. P., Stark, D., Verduzco, L., van Dyck, C. H. & Arnsten, A. F. Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learn Mem. 13, 770\u2013776 (2006).","journal-title":"Learn Mem."},{"key":"1381_CR34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0165-1838(97)00086-6","volume":"66","author":"M Kawamura","year":"1997","unstructured":"Kawamura, M. et al. Effects of aldehyde\/aldose reductase inhibition on neuronal metabolism of norepinephrine. J. Auton. Nerv. Syst. 66, 145\u2013148 (1997).","journal-title":"J. Auton. Nerv. Syst."},{"key":"1381_CR35","doi-asserted-by":"publisher","first-page":"8771","DOI":"10.1523\/JNEUROSCI.22-19-08771.2002","volume":"22","author":"JS Franowicz","year":"2002","unstructured":"Franowicz, J. S. et al. Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J. Neurosci. 22, 8771\u20138777 (2002).","journal-title":"J. Neurosci."},{"key":"1381_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0091-3057(96)00111-6","volume":"55","author":"P Rama","year":"1996","unstructured":"Rama, P., Linnankoski, I., Tanila, H., Pertovaara, A. & Carlson, S. Medetomidine, atipamezole, and guanfacine in delayed response performance of aged monkeys. Pharm. Biochem. Behav. 55, 415\u2013422 (1996).","journal-title":"Pharm. Biochem. Behav."},{"key":"1381_CR37","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0893-133X(00)00111-1","volume":"23","author":"RA Avery","year":"2000","unstructured":"Avery, R. A., Franowicz, J. S., Studholme, C., van Dyck, C. H. & Arnsten, A. F. The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology 23, 240\u2013249 (2000).","journal-title":"Neuropsychopharmacology"},{"key":"1381_CR38","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1111\/j.1460-9568.2011.07815.x","volume":"34","author":"E Decamp","year":"2011","unstructured":"Decamp, E., Clark, K. & Schneider, J. S. Effects of the alpha-2 adrenoceptor agonist guanfacine on attention and working memory in aged non-human primates. Eur. J. Neurosci. 34, 1018\u20131022 (2011).","journal-title":"Eur. J. Neurosci."},{"key":"1381_CR39","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.brainres.2004.07.062","volume":"1024","author":"M Wang","year":"2004","unstructured":"Wang, M., Tang, Z. X. & Li, B. M. Enhanced visuomotor associative learning following stimulation of alpha 2A-adrenoceptors in the ventral prefrontal cortex in monkeys. Brain Res. 1024, 176\u2013182 (2004).","journal-title":"Brain Res"},{"key":"1381_CR40","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1523\/JNEUROSCI.08-11-04287.1988","volume":"8","author":"AF Arnsten","year":"1988","unstructured":"Arnsten, A. F., Cai, J. X. & Goldman-Rakic, P. S. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J. Neurosci. 8, 4287\u20134298 (1988).","journal-title":"J. Neurosci."},{"key":"1381_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ynstr.2015.01.001","volume":"2","author":"AB Hains","year":"2015","unstructured":"Hains, A. B., Yabe, Y. & Arnsten, A. F. Chronic stimulation of alpha-2A-adrenoceptors with guanfacine protects rodent prefrontal cortex dendritic spines and cognition from the effects of chronic stress. Neurobiol. Stress 2, 1\u20139 (2015).","journal-title":"Neurobiol. Stress"},{"key":"1381_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1744-9081-2-41","volume":"2","author":"T Sagvolden","year":"2006","unstructured":"Sagvolden, T. The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of attention-deficit\/hyperactivity disorder (ADHD). Behav. Brain Funct. 2, 41 (2006).","journal-title":"Behav. Brain Funct."},{"key":"1381_CR43","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2007.03.015","volume":"129","author":"M Wang","year":"2007","unstructured":"Wang, M. et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 129, 397\u2013410 (2007).","journal-title":"Cell"},{"key":"1381_CR44","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S0893-133X(01)00249-4","volume":"25","author":"JI Friedman","year":"2001","unstructured":"Friedman, J. I. et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 25, 402\u2013409 (2001).","journal-title":"Neuropsychopharmacology"},{"key":"1381_CR45","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.biopsych.2006.06.034","volume":"61","author":"MM McClure","year":"2007","unstructured":"McClure, M. M. et al. The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. Biol. Psychiatry 61, 1157\u20131160 (2007).","journal-title":"Biol. Psychiatry"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01381-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01381-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01381-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T08:02:38Z","timestamp":1669881758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01381-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["1381"],"URL":"https:\/\/doi.org\/10.1038\/s41398-021-01381-z","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,3]]},"assertion":[{"value":"23 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"262"}}